Scancell Holdings Plc Block Listing Six Monthly Return
April 16 2024 - 1:00AM
RNS Regulatory News
RNS Number : 6862K
Scancell Holdings Plc
16 April 2024
Scancell Holdings plc
("Scancell" or the
"Company")
Block
Listing Six Monthly Return
Scancell Holdings plc (AIM: SCLP), the
developer of novel immunotherapies for the treatment of
cancer, today makes the
following notification pursuant to Schedule Six of the AIM Rules
for Companies regarding its existing block admission
arrangements:
|
Name of applicant:
|
Scancell Holdings plc
|
|
Number and class of securities
originally admitted:
|
2,880,000 ordinary shares of £0.001
each
|
|
Date of admission:
|
17 April 2023
|
|
Period of return:
|
From:
|
17 October 2023
|
To:
|
16 April 2024
|
|
Balance of unallotted securities
under scheme(s) from previous return:
|
1,620,000
|
|
Plus: The amount by which the block
scheme(s) has been increased since the date of the last return (if
any increase has been applied for):
|
0
|
|
Less: Number of securities
issued/allotted under scheme(s) during period (see
LR3.5.7G):
|
1,000,000
|
|
Equals: Balance under scheme(s) not yet
issued/allotted at end of period:
|
620,000
|
|
Total number
of securities in issue at the end of the
period
|
928,979,977
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
For further
information, please contact:
|
|
|
Scancell
Holdings plc
|
+44 (0) 20 3709 5700
|
|
Professor Lindy Durrant, CEO
Dr Jean-Michel Cosséry, Non-Executive
Chairman
|
|
|
Stifel Nicolaus
Europe Limited (Nominated Adviser and Joint Broker)
|
+44 (0) 20 7710 7600
|
|
Nicholas Moore/Samira Essebiyea (Healthcare
Investment Banking)
Nick Adams/Nick Harland (Corporate Broking)
|
|
|
WG
Partners LLP (Joint Broker)
David Wilson/Claes Spang/Sathesh
Nadarajah/Erland Sternby
|
+44 (0) 20 3705 9330
|
|
Panmure Gordon (UK)
Limited (Joint Broker)
|
+44 (0) 20 7886 2500
|
|
Freddy Crossley/Emma Earl (Corporate Finance)
|
|
|
Rupert Dearden (Corporate Broking)
|
|
About
Scancell
Scancell is a clinical stage
biopharmaceutical company that is leveraging its proprietary
research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant
unmet needs in cancer. The Company is building a pipeline of
innovative products by utilising its four technology platforms:
Moditope® and
ImmunoBody® for vaccines and
GlyMab® and AvidiMab® for antibodies.
Adaptive immune responses include
antibodies and T cells (CD4 and CD8), both of which can recognise
damaged or infected cells. In order to destroy such cancerous or
infected cells, Scancell uses either vaccines to induce immune
responses or monoclonal antibodies (mAbs) to redirect immune cells
or drugs. The Company's unique approach is that its innovative
products target modifications of proteins and lipids. For the
vaccines (Moditope® and
ImmunoBody®) this includes
citrullination and homocitrullination of proteins, whereas its mAb
portfolio targets glycans or sugars that are added onto proteins
and / or lipids (GlyMab®) or enhances the potency of
antibodies and their ability to directly kill tumour cells
(AvidiMab®).
For further information about
Scancell, please visit: https://www.scancell.co.uk/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
BLRBUGDSDUBDGSU
Scancell (LSE:SCLP)
Historical Stock Chart
From Oct 2024 to Nov 2024
Scancell (LSE:SCLP)
Historical Stock Chart
From Nov 2023 to Nov 2024
